Profile: Therakos, Inc. USA specializes in the field of photopheresis and immune cell therapy. We offer Therakos™ Cellex™ photopheresis system for the palliative (reducing the severity of symptoms) treatment of the skin manifestations (appearance) of cutaneous T-cell lymphoma (CTCL) that are unresponsive to other forms of treatment. The Therakos™ Cellex™ photopheresis system is an easy-to-use, integrated system that uses extracorporeal (outside the body) photopheresis (ECP), a cellular therapy, to relieve the symptoms of CTCL. The Cellex™ photopheresis system features several improvements designed to enhance the patient treatment experience, such as shorter treatment times and reduced extracorporeal blood volume. The benefits of reduced risk of infection and reinfusion errors are maintained in the Cellex™ photopheresis system. Specific features of this system include an automated, closed system design that provides users the ability to switch between double and single needle treatment, if necessary. The system also utilizes a separation technology to separate white blood cells from whole blood.

The company has ~50 employees and is ISO 9001, CE certified. NYSE:JNJ (SEC Filings)